Plain-English translation of NCT06978439 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Kawasaki Disease research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether rivaroxaban, a blood thinner medication, can safely prevent blood clots in children who developed giant coronary artery aneurysms (abnormal bulges in heart blood vessels) after having Kawasaki disease. Children with this serious heart complication are at high risk for life-threatening blood clots, and doctors currently use older blood-thinning treatments. The medication has been approved for other uses in children, but this study will examine whether it works well for this specific heart problem, especially in Asian children who may need different doses.
Children who develop large aneurysms in their heart arteries after Kawasaki disease face a lifetime risk of dangerous blood clots and heart emergencies. Current treatments with older blood thinners can be inconvenient and risky, especially when combined with the antiplatelet drugs these children also need to take. This trial aims to find out if this newer blood thinner medication can be safer and more effective for these children.
You likely qualify if…
You likely don't qualify if…
You would give your child the medication by mouth in a dose adjusted for their age and weight, along with continuing any antiplatelet medicines their doctor recommends. The trial will last about 6 months, during which you'll have regular visits with the research team to check your child's health, do blood tests to make sure the medication is working safely, and monitor for any bleeding or clotting problems. The researchers will use blood tests and heart imaging to track how well the medication is preventing clots while keeping your child safe.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China